GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MultiCell Technologies Inc (OTCPK:MCET) » Definitions » Piotroski F-Score

MultiCell Technologies (MultiCell Technologies) Piotroski F-Score : 0 (As of Jun. 03, 2024)


View and export this data going back to . Start your Free Trial

What is MultiCell Technologies Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MultiCell Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for MultiCell Technologies's Piotroski F-Score or its related term are showing as below:


MultiCell Technologies Piotroski F-Score Historical Data

The historical data trend for MultiCell Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MultiCell Technologies Piotroski F-Score Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 2.00 2.00 -

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Aug15) TTM:Last Year (Aug14) TTM:
Net Income was -0.003 + -0.262 + 0.171 + -0.159 = $-0.25 Mil.
Cash Flow from Operations was -0.299 + -0.126 + 0.307 + -0.079 = $-0.20 Mil.
Revenue was 0.012 + 0.012 + 0.586 + 0.195 = $0.81 Mil.
Gross Profit was 0.012 + 0.012 + 0.586 + 0.046 = $0.66 Mil.
Average Total Assets from the begining of this year (Aug14)
to the end of this year (Aug15) was
(0.144 + 0.126 + 0.066 + 0.421 + 0.296) / 5 = $0.2106 Mil.
Total Assets at the begining of this year (Aug14) was $0.14 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.30 Mil.
Total Current Liabilities was $1.54 Mil.
Net Income was -0.331 + -0.28 + -0.322 + 0.225 = $-0.71 Mil.

Revenue was 0.012 + 0.012 + 0.012 + 0.012 = $0.05 Mil.
Gross Profit was 0.012 + 0.012 + 0.012 + 0.012 = $0.05 Mil.
Average Total Assets from the begining of last year (Aug13)
to the end of last year (Aug14) was
(0.324 + 0.179 + 0.267 + 0.183 + 0.144) / 5 = $0.2194 Mil.
Total Assets at the begining of last year (Aug13) was $0.32 Mil.
Long-Term Debt & Capital Lease Obligation was $0.04 Mil.
Total Current Assets was $0.14 Mil.
Total Current Liabilities was $1.30 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MultiCell Technologies's current Net Income (TTM) was -0.25. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

MultiCell Technologies's current Cash Flow from Operations (TTM) was -0.20. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Aug14)
=-0.253/0.144
=-1.75694444

ROA (Last Year)=Net Income/Total Assets (Aug13)
=-0.708/0.324
=-2.18518519

MultiCell Technologies's return on assets of this year was -1.75694444. MultiCell Technologies's return on assets of last year was -2.18518519. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

MultiCell Technologies's current Net Income (TTM) was -0.25. MultiCell Technologies's current Cash Flow from Operations (TTM) was -0.20. ==> -0.20 > -0.25 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Aug15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Aug14 to Aug15
=0/0.2106
=0

Gearing (Last Year: Aug14)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Aug13 to Aug14
=0.038/0.2194
=0.17319964

MultiCell Technologies's gearing of this year was 0. MultiCell Technologies's gearing of last year was 0.17319964. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Aug15)=Total Current Assets/Total Current Liabilities
=0.295/1.537
=0.19193234

Current Ratio (Last Year: Aug14)=Total Current Assets/Total Current Liabilities
=0.144/1.297
=0.11102544

MultiCell Technologies's current ratio of this year was 0.19193234. MultiCell Technologies's current ratio of last year was 0.11102544. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

MultiCell Technologies's number of shares in issue this year was 5000.949. MultiCell Technologies's number of shares in issue last year was 5072.337. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.656/0.805
=0.81490683

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.048/0.048
=1

MultiCell Technologies's gross margin of this year was 0.81490683. MultiCell Technologies's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Aug14)
=0.805/0.144
=5.59027778

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Aug13)
=0.048/0.324
=0.14814815

MultiCell Technologies's asset turnover of this year was 5.59027778. MultiCell Technologies's asset turnover of last year was 0.14814815. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

MultiCell Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.

MultiCell Technologies  (OTCPK:MCET) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


MultiCell Technologies Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of MultiCell Technologies's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MultiCell Technologies (MultiCell Technologies) Business Description

Traded in Other Exchanges
N/A
Address
68 Cumberland Street, Suite 301, Woonsocket, RI, USA, 02895
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.
Executives
Stephen Chang director 12912 CAMINO DEL VALLE, POWAY CA 92064
Anthony E Altig director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, JERSEY CITY NJ 07302
Gregory F Szabo director, officer: President and Treasurer 14505 N. HAYDEN ROAD, #305, SCOTTSDALE AZ 85260

MultiCell Technologies (MultiCell Technologies) Headlines

No Headlines